SCAF11

Summary

SCAF11 (SR-related CTD associated factor 11, HGNC:10784) is a protein-coding gene on chromosome 12q12, encoding Protein SCAF11 (Q99590). Plays a role in pre-mRNA alternative splicing by regulating spliceosome assembly.

Enables RNA binding activity. Involved in spliceosomal complex assembly. Located in nuclear body and nucleolus.

Source: NCBI Gene 9169 — RefSeq curated summary.

At a glance

• GWAS associations: 9
• Clinical variants (ClinVar): 201 total — 1 likely-pathogenic
• MANE Select transcript: NM_004719

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10784
Approved symbol	SCAF11
Name	SR-related CTD associated factor 11
Location	12q12
Locus type	gene with protein product
Status	Approved
Aliases	SIP1, SRRP129, CASP11
Ensembl gene	ENSG00000139218
Ensembl biotype	protein_coding
OMIM	603668
Entrez	9169

Gene structure

Transcript identifiers

Ensembl transcripts: 19 — 12 protein_coding, 3 retained_intron, 3 protein_coding_CDS_not_defined, 1 non_stop_decay

ENST00000266589, ENST00000369367, ENST00000395453, ENST00000395454, ENST00000465950, ENST00000474828, ENST00000484275, ENST00000546534, ENST00000547018, ENST00000547654, ENST00000547950, ENST00000549162, ENST00000550629, ENST00000550893, ENST00000551391, ENST00000884498, ENST00000943612, ENST00000943613, ENST00000943614

RefSeq mRNA: 1 — MANE Select: NM_004719 NM_004719

CCDS: CCDS8748

Canonical transcript exons

ENST00000369367 — 15 exons

Exon	Start	End
ENSE00000887974	45924728	45925074
ENSE00001648848	45951650	45951727
ENSE00001700360	45945249	45945313
ENSE00001722333	45948437	45948537
ENSE00001768974	45961700	45961857
ENSE00001800405	45926142	45928859
ENSE00003491482	45934176	45934285
ENSE00003511524	45931506	45931612
ENSE00003514236	45964107	45964188
ENSE00003522582	45919131	45922194
ENSE00003536357	45934447	45934505
ENSE00003544698	45922936	45923154
ENSE00003616882	45922463	45922582
ENSE00003653970	45933131	45933232
ENSE00003850068	45990353	45990574

Expression profiles

Bgee: expression breadth ubiquitous, 295 present calls, max score 98.71.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 48.8720 / max 555.5009, expressed in 1823 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
130564	38.2259	1818
130563	6.7718	1711
130567	1.5642	828
130562	0.8550	589
130561	0.5778	319
130565	0.4786	241
130566	0.3985	211

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	98.71	gold quality
colonic epithelium	UBERON:0000397	98.40	gold quality
tendon of biceps brachii	UBERON:0008188	98.35	gold quality
calcaneal tendon	UBERON:0003701	98.27	gold quality
tendon	UBERON:0000043	98.06	gold quality
lower lobe of lung	UBERON:0008949	97.58	gold quality
jejunal mucosa	UBERON:0000399	97.55	gold quality
pylorus	UBERON:0001166	97.46	gold quality
tonsil	UBERON:0002372	97.31	gold quality
oral cavity	UBERON:0000167	97.30	gold quality
sural nerve	UBERON:0015488	97.29	gold quality
visceral pleura	UBERON:0002401	97.24	gold quality
bone marrow cell	CL:0002092	97.17	gold quality
cervix squamous epithelium	UBERON:0006922	97.10	gold quality
superficial temporal artery	UBERON:0001614	97.01	gold quality
superior surface of tongue	UBERON:0007371	97.00	gold quality
jejunum	UBERON:0002115	96.97	gold quality
olfactory bulb	UBERON:0002264	96.89	gold quality
cardia of stomach	UBERON:0001162	96.85	gold quality
trabecular bone tissue	UBERON:0002483	96.83	gold quality
mucosa of paranasal sinus	UBERON:0005030	96.70	gold quality
adrenal tissue	UBERON:0018303	96.66	gold quality
skin of hip	UBERON:0001554	96.62	gold quality
nipple	UBERON:0002030	96.45	gold quality
blood vessel layer	UBERON:0004797	96.37	gold quality
bone marrow	UBERON:0002371	96.34	gold quality
gluteal muscle	UBERON:0002000	96.31	gold quality
tibia	UBERON:0000979	96.30	gold quality
monocyte	CL:0000576	96.24	gold quality
parietal pleura	UBERON:0002400	96.19	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-6379	no	2257.16
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

200 targeting SCAF11, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-539-3P	99.98	70.74	1616

Literature-anchored findings (GeneRIF, showing 3)

• Sip1 C-terminal is a novel autoantigen in Behcet’s disease. IgM specific to Sip1 C-ter might be useful in clinical practice as an immunological marker of endothelial dysfunction in vasculitis. (PMID:16611372)
• Regulation, Activation and Function of Caspase-11 during Health and Disease. (PMID:33546173)
• CASP4/11 Contributes to NLRP3 Activation and COVID-19 Exacerbation. (PMID:36763010)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	scaf11	ENSDARG00000045885
mus_musculus	Scaf11	ENSMUSG00000033228
rattus_norvegicus	Scaf11	ENSRNOG00000005263
drosophila_melanogaster	CG2926	FBGN0037344

Paralogs (2): PHRF1 (ENSG00000070047), SCAF1 (ENSG00000126461)

Protein

Protein identifiers

Protein SCAF11 — Q99590 (reviewed: Q99590)

Alternative names: CTD-associated SR protein 11, Renal carcinoma antigen NY-REN-40, SC35-interacting protein 1, SR-related and CTD-associated factor 11, SRSF2-interacting protein, Serine/arginine-rich splicing factor 2-interacting protein, Splicing factor, arginine/serine-rich 2-interacting protein, Splicing regulatory protein 129

All UniProt accessions (8): A0A087WTB7, A0A087WUE7, A0A0A0MTP7, A8MTP4, A8MUK0, Q99590, F8VXG7, F8W6K1

UniProt curated annotations — full annotation on UniProt →

Function. Plays a role in pre-mRNA alternative splicing by regulating spliceosome assembly.

Subunit / interactions. Interacts with SRSF2/SFRS2, U2AF2 and SNRNP70.

Subcellular location. Nucleus.

Tissue specificity. Widely expressed.

Isoforms (2)

UniProt ID	Names	Canonical?
Q99590-1	1	yes
Q99590-2	2

RefSeq proteins (1): NP_004710* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001841	Znf_RING	Domain
IPR013083	Znf_RING/FYVE/PHD	Homologous_superfamily
IPR017907	Znf_RING_CS	Conserved_site
IPR057031	SFR19-like_C	Domain

Pfam: PF13639, PF23030

UniProt features (71 total): modified residue 34, compositionally biased region 17, cross-link 7, region of interest 6, sequence variant 2, sequence conflict 2, chain 1, zinc finger region 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q99590-F1	42.56	0.06

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (41): 331, 338, 341, 344, 400, 401, 402, 405, 410, 413, 533, 588, 608, 614, 680, 687, 694, 723, 726, 769 …

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 231 (showing top): GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, chr12q12, MARTINEZ_RB1_TARGETS_UP, GROSS_HYPOXIA_VIA_ELK3_DN, GOBP_PROTEIN_RNA_COMPLEX_ORGANIZATION, GOBP_RNA_SPLICING, PU1_Q6, FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_REJECTED_VS_OK_DN, GNF2_DDX5, DBP_Q6, GOBP_RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS, SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_DN, MARIADASON_RESPONSE_TO_BUTYRATE_SULINDAC_6, RAAGNYNNCTTY_UNKNOWN, GOCC_NUCLEAR_BODY

GO Biological Process (4): spliceosomal complex assembly (GO:0000245), RNA splicing, via transesterification reactions (GO:0000375), mRNA processing (GO:0006397), RNA splicing (GO:0008380)

GO Molecular Function (4): RNA binding (GO:0003723), zinc ion binding (GO:0008270), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (4): nucleoplasm (GO:0005654), nucleolus (GO:0005730), nuclear body (GO:0016604), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA processing	2
nuclear lumen	2
intracellular membraneless organelle	2
mRNA splicing, via spliceosome	1
protein-RNA complex assembly	1
RNA splicing	1
mRNA metabolic process	1
nucleic acid binding	1
transition metal ion binding	1
binding	1
cation binding	1
cellular anatomical structure	1
nucleoplasm	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1710 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SCAF11	PNISR	Q8TF01	869
SCAF11	CASP4	P49662	860
SCAF11	U2AF2	P26368	794
SCAF11	SRSF2	Q01130	711
SCAF11	CASP1	P29466	704
SCAF11	CASP8	Q14790	675
SCAF11	GSDMB	Q8TAX9	659
SCAF11	RASA4	O43374	624
SCAF11	GSDMC	Q9BYG8	619
SCAF11	PJVK	Q0ZLH3	606
SCAF11	CASP5	P51878	600
SCAF11	GSDME	O60443	584
SCAF11	GSDMD	P57764	571
SCAF11	IL1B	P01584	558
SCAF11	NLRP7	Q8WX94	547

IntAct

108 interactions, top by confidence:

A	B	Type	Score
POLR2J	POLR1C	psi-mi:“MI:0914”(association)	0.830
PRMT8	SYNCRIP	psi-mi:“MI:0914”(association)	0.830
RPRD1B	POLR2D	psi-mi:“MI:0914”(association)	0.730
U2AF1	U2AF2	psi-mi:“MI:0914”(association)	0.670
U2AF2	SCAF11	psi-mi:“MI:0915”(physical association)	0.640
APBA3	DUSP11	psi-mi:“MI:0914”(association)	0.530
SUPT5H	POLR2D	psi-mi:“MI:0914”(association)	0.530
YWHAZ	BLTP3B	psi-mi:“MI:0914”(association)	0.530
TRPC4AP	SMCHD1	psi-mi:“MI:0914”(association)	0.530
LUC7L2	CASC3	psi-mi:“MI:0914”(association)	0.530
SRPK2	RRP9	psi-mi:“MI:0914”(association)	0.530
EZH1	EPOP	psi-mi:“MI:0914”(association)	0.530
ABT1	ZNF316	psi-mi:“MI:0914”(association)	0.530
RPL13	RRP8	psi-mi:“MI:0914”(association)	0.530
CPSF6	DDX39A	psi-mi:“MI:0914”(association)	0.480
U2AF2	U2SURP	psi-mi:“MI:0914”(association)	0.480
SCAF11	PSIP1	psi-mi:“MI:0915”(physical association)	0.400
LGALSL	SCAF11	psi-mi:“MI:0915”(physical association)	0.400
S100A9	SCAF11	psi-mi:“MI:0915”(physical association)	0.370
SCAF11	STAT3	psi-mi:“MI:0915”(physical association)	0.370
SCAF11	MRPL3	psi-mi:“MI:0914”(association)	0.350
MKI67	ARHGAP10	psi-mi:“MI:0914”(association)	0.350
Mecom	ESYT2	psi-mi:“MI:0914”(association)	0.350
ESR1	ESYT2	psi-mi:“MI:0914”(association)	0.350
CUL4A	HAX1	psi-mi:“MI:0914”(association)	0.350
TRPC4AP	SMCHD1	psi-mi:“MI:0914”(association)	0.350

BioGRID (161): SCAF11 (Affinity Capture-MS), SCAF11 (Affinity Capture-MS), SCAF11 (Affinity Capture-MS), SLC25A6 (Affinity Capture-MS), LGALS3BP (Affinity Capture-MS), TUBG1 (Affinity Capture-MS), TUBGCP3 (Affinity Capture-MS), TUBGCP2 (Affinity Capture-MS), MRPL3 (Affinity Capture-MS), TUBGCP4 (Affinity Capture-MS), NME7 (Affinity Capture-MS), ZNFX1 (Affinity Capture-MS), C2orf44 (Affinity Capture-MS), TUBGCP6 (Affinity Capture-MS), TUBGCP5 (Affinity Capture-MS)

ESM2 similar proteins: A0JM80, A0JNH1, A0JNH9, A3KMW7, A6NMK8, A6QNQ6, B0BM16, B1H1S4, B1WC58, B2GUZ2, D3Z987, D3ZF42, E7FAP1, F6SNN2, P23497, P70347, Q0P5X5, Q14B71, Q283Q6, Q29RT4, Q2M2Z5, Q3U0P1, Q3ULM6, Q3UXL4, Q3V089, Q571C7, Q5HZI1, Q5R9I1, Q5RD97, Q5W0B1, Q6GNV6, Q6KAQ7, Q6P1D7, Q6PDM4, Q7TSY8, Q7ZZH7, Q80WQ8, Q80YR6, Q86YC2, Q8BUH8

Diamond homologs: A1YVX4, A2A8L1, A2AUY4, A2BIL7, A6H619, A7E320, A8DZJ1, A9LMC0, B6CHA3, B7ZS37, B9RU15, C4QVX6, D3ZD32, E7EZF3, F4I240, F4JYC8, F4KE59, F6UA42, G5EBZ4, O43918, O88379, O94400, O97159, P29375, P41229, P41230, P46605, P47156, P48786, P56163, P58268, P58269, P58270, Q04996, Q09477, Q12830, Q12873, Q14839, Q23541, Q23590

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
Ub:E2	“up-regulates activity”	SCAF11	ubiquitination
SCAF11	“up-regulates activity”	PSEN1	cleavage

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 133 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
mRNA 3’-end processing	11	23.8×	7e-11
RNA Polymerase II Transcription Termination	9	21.7×	2e-08
Transport of Mature Transcript to Cytoplasm	5	20.9×	2e-04
mRNA Splicing	17	20.5×	6e-16
mRNA Polyadenylation	21	20.3×	2e-19
mRNA Splicing - Minor Pathway	8	19.7×	4e-07
Processing of Capped Intron-Containing Pre-mRNA	19	17.1×	2e-16
Transport of Mature mRNA derived from an Intron-Containing Transcript	9	15.1×	5e-07

GO biological processes:

GO term	Partners	Fold	FDR
mRNA splicing, via spliceosome	17	12.7×	2e-11
RNA processing	7	12.5×	3e-04
regulation of alternative mRNA splicing, via spliceosome	6	11.9×	1e-03
negative regulation of translation	7	11.2×	5e-04
ribosomal small subunit biogenesis	5	9.3×	9e-03
RNA splicing	12	8.6×	4e-06
mRNA processing	13	8.3×	2e-06
rRNA processing	7	8.1×	2e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

201 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	169
Likely benign	13
Benign	3

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
815524	GRCh37/hg19 12q12(chr12:46141773-46375955)x1	Likely pathogenic

SpliceAI

2133 predictions. Top by Δscore:

Variant	Effect	Δscore
12:45922458:CTT:C	donor_loss	1.0000
12:45922461:A:AC	donor_gain	1.0000
12:45922461:ACTTT:A	donor_loss	1.0000
12:45922462:C:CC	donor_gain	1.0000
12:45922500:T:TA	donor_gain	1.0000
12:45922578:AATTT:A	acceptor_gain	1.0000
12:45922579:ATTT:A	acceptor_gain	1.0000
12:45922580:TTT:T	acceptor_gain	1.0000
12:45922581:TT:T	acceptor_gain	1.0000
12:45922582:TCTG:T	acceptor_loss	1.0000
12:45922583:C:A	acceptor_loss	1.0000
12:45922583:C:CC	acceptor_gain	1.0000
12:45922586:A:AC	acceptor_gain	1.0000
12:45922586:A:C	acceptor_gain	1.0000
12:45925075:C:CC	acceptor_gain	1.0000
12:45926140:AC:A	donor_gain	1.0000
12:45926141:CC:C	donor_gain	1.0000
12:45931499:A:AC	donor_gain	1.0000
12:45931500:C:CC	donor_gain	1.0000
12:45931528:A:AC	donor_gain	1.0000
12:45931529:C:CC	donor_gain	1.0000
12:45931608:CAATT:C	acceptor_gain	1.0000
12:45931871:A:C	donor_gain	1.0000
12:45933228:CTGTA:C	acceptor_gain	1.0000
12:45933233:C:CC	acceptor_gain	1.0000
12:45934174:A:AC	donor_gain	1.0000
12:45934175:C:CC	donor_gain	1.0000
12:45934286:C:CC	acceptor_gain	1.0000
12:45945247:A:AC	donor_gain	1.0000
12:45945248:C:CT	donor_gain	1.0000

AlphaMissense

9689 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:45922142:A:T	V1433D	1.000
12:45922145:A:G	L1432P	1.000
12:45922145:A:T	L1432Q	1.000
12:45922463:T:A	K1415N	1.000
12:45922463:T:G	K1415N	1.000
12:45922465:T:C	K1415E	1.000
12:45922474:C:G	A1412P	1.000
12:45922479:C:G	R1410P	1.000
12:45922485:A:C	I1408S	1.000
12:45922485:A:T	I1408N	1.000
12:45922490:T:A	K1406N	1.000
12:45922490:T:G	K1406N	1.000
12:45922495:A:G	Y1405H	1.000
12:45922502:C:A	K1402N	1.000
12:45922502:C:G	K1402N	1.000
12:45922509:A:C	I1400S	1.000
12:45922509:A:T	I1400N	1.000
12:45922525:A:C	Y1395D	1.000
12:45922536:A:T	I1391N	1.000
12:45922539:G:T	A1390D	1.000
12:45922540:C:G	A1390P	1.000
12:45922122:A:C	Y1440D	0.999
12:45922125:T:C	K1439E	0.999
12:45922130:A:T	V1437E	0.999
12:45922134:A:C	Y1436D	0.999
12:45922134:A:G	Y1436H	0.999
12:45922137:C:G	A1435P	0.999
12:45922143:C:A	V1433F	0.999
12:45922154:A:T	V1429E	0.999
12:45922156:T:A	K1428N	0.999

dbSNP variants (sampled 300 via entrez): RS1000007424 (12:45923594 A>G), RS1000050747 (12:45921304 T>C), RS1000066879 (12:45976791 TA>T), RS1000078570 (12:45967305 A>G), RS1000174931 (12:45924695 A>G), RS1000186620 (12:45929226 T>C), RS1000225918 (12:45951873 T>C), RS1000227122 (12:45932596 C>G), RS1000256894 (12:45951486 A>T), RS1000307007 (12:45993834 C>G), RS1000313861 (12:45982472 C>A), RS1000314262 (12:45937330 T>C), RS1000322999 (12:45929470 T>C), RS1000356162 (12:45982134 C>T), RS1000371586 (12:45988478 A>C)

Disease associations

OMIM: gene MIM:603668 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): breast ductal adenocarcinoma (MONDO:0005590)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST000461_8	Hippocampal atrophy	8.000000e-06
GCST005194_251	Coronary artery disease	2.000000e-07
GCST007565_39	Morning person	1.000000e-15
GCST009325_10	Parkinson’s disease or first degree relation to individual with Parkinson’s disease	4.000000e-08
GCST009391_1757	Metabolite levels	5.000000e-07
GCST009597_216	Multiple sclerosis	6.000000e-07
GCST010002_216	Refractive error	2.000000e-29
GCST010083_255	Hemoglobin levels	2.000000e-11
GCST010142_31	Fish- and plant-related diet	7.000000e-09

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0005039	hippocampal atrophy
EFO:0008328	chronotype measurement
EFO:0010370	lysophosphatidylethanolamine 20:4 measurement
EFO:0004509	hemoglobin measurement
EFO:0008111	diet measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D018270	Carcinoma, Ductal, Breast	C04.557.470.200.025.232.500; C04.557.470.615.132.500; C04.588.180.390; C17.800.090.500.390

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

55 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression	6
trichostatin A	affects expression, increases expression	2
sodium arsenite	affects methylation, affects cotreatment, increases abundance, increases expression	2
Acetaminophen	decreases expression	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	2
Cadmium Chloride	increases abundance, increases expression, decreases expression	2
aristolochic acid I	decreases expression	1
afuresertib	decreases expression	1
FR900359	affects phosphorylation	1
TAK-243	increases sumoylation	1
testosterone enanthate	affects expression	1
methylmercuric chloride	decreases expression	1
bisphenol A	increases expression	1
lead acetate	increases expression, affects cotreatment	1
methylparaben	decreases expression	1
mono-(2-ethylhexyl)phthalate	increases methylation, increases abundance	1
zinc protoporphyrin	affects cotreatment, increases expression	1
manganese chloride	increases abundance, increases expression, affects cotreatment	1
coumarin	affects phosphorylation	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
torcetrapib	increases expression	1
bisphenol S	affects cotreatment, increases methylation	1
jinfukang	decreases expression	1
NSC 689534	increases expression, affects binding	1
Resveratrol	affects cotreatment, increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Arsenic	increases expression, affects cotreatment, increases abundance	1
Cadmium	increases abundance, increases expression	1
Caffeine	affects phosphorylation	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2EL	Abcam HeLa SCAF11 KO	Cancer cell line	Female

Clinical trials (associated diseases)

11 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03414970	PHASE3	ACTIVE_NOT_RECRUITING	Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT00461344	PHASE2	TERMINATED	Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
NCT07499999	PHASE2	NOT_YET_RECRUITING	Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
NCT00637364	PHASE1/PHASE2	SUSPENDED	High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain
NCT02779855	PHASE1/PHASE2	COMPLETED	Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
NCT01753908	EARLY_PHASE1	COMPLETED	Broccoli Sprout Extract in Treating Patients With Breast Cancer
NCT01796041	EARLY_PHASE1	COMPLETED	Intraoperative Imaging of Breast Cancer With Indocyanine Green
NCT01208974	Not specified	ACTIVE_NOT_RECRUITING	Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction
NCT01875198	Not specified	TERMINATED	Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer
NCT03543397	Not specified	UNKNOWN	MRI in Ductal Carcinoma in Situ (DCIS)
NCT03834532	Not specified	COMPLETED	Living Well After Breast Surgery